Artelo Biosciences (ARTL) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
A special meeting of stockholders is scheduled for August 28, 2025, to vote on key amendments and auditor ratification.
The meeting will be held virtually, allowing shareholders to participate and vote online.
Record date for voting eligibility is July 25, 2025, with 704,425 shares of common stock outstanding.
Voting matters and shareholder proposals
Proposal 1 seeks to increase authorized common stock from 8,333,333 to 500,000,000 shares.
Proposal 2 aims to increase authorized preferred stock from 69,444 to 10,000,000 shares, with rights determined by the board.
Proposal 3 is for ratification of MaloneBailey, LLP as independent auditor for fiscal year 2025.
Board recommends voting FOR all proposals.
Shareholder proposals for the 2025 annual meeting must comply with Rule 14a-8 and company bylaws.
Board of directors and corporate governance
Board and management have no undisclosed interests in the matters to be acted upon.
No 5% beneficial owners; directors and officers as a group own 5.8% of outstanding shares.
Latest events from Artelo Biosciences
- Biopharma registers 9.8M shares for resale, targeting unmet needs but facing dilution risks.ARTL
Registration filing7 Apr 2026 - Equity line agreement enables up to $50M in funding but poses dilution and market risks.ARTL
Registration filing24 Mar 2026 - Biopharma seeks $10.9M via equity/warrants to fund clinical pipeline amid Nasdaq compliance risks.ARTL
Registration filing24 Mar 2026 - Lead programs show strong clinical progress in cancer anorexia, neuropathy, and anxiety.ARTL
Corporate presentation24 Mar 2026 - Biopharma seeks up to $10.8M via share/warrant offering to fund clinical pipeline, with dilution risk.ARTL
Registration filing23 Mar 2026 - Biopharma seeks $10.8M via stock and warrants to fund clinical pipeline, facing dilution and listing risks.ARTL
Registration filing20 Mar 2026 - Strong clinical advances offset by higher net loss and lower cash reserves in 2025.ARTL
Q4 202524 Feb 2026 - Net loss narrowed, cash runway extends into Q4 2025, and key clinical milestones are expected.ARTL
Q3 20245 Feb 2026 - All proposals passed, with directors re-elected and no shareholder questions submitted.ARTL
AGM 20262 Feb 2026 - Promising clinical pipeline in pain, cancer, and mental health, backed by strong IP and leadership.ARTL
Investor presentation30 Jan 2026